PHSA

WELL Health Announces the Creation of a Dedicated Public Sector Group to Help Tech Enable Public Health Systems Operating at Scale

Retrieved on: 
Wednesday, February 7, 2024

WELL has created a dedicated public sector focused group to support large scale health systems and care delivery networks that underpin the public sector.

Key Points: 
  • WELL has created a dedicated public sector focused group to support large scale health systems and care delivery networks that underpin the public sector.
  • The objective of this group is to combine and deliver product offerings that are specifically suited for public sector's unique scale and requirements.
  • WELL's public sector offerings leverage WELL's operating strengths which include Canada's leading provider-centric technology platform and the largest network of outpatient clinics in Canada.
  • This has given us tremendous insights into our public health ecosystem and positions us to be valuable to our public health partners."

Anderson College's New Medical Radiography Technology Program to Address Massive Industry Shortages

Retrieved on: 
Tuesday, January 23, 2024

VANCOUVER, BC, Jan. 23, 2024 /CNW/ - Anderson College is proud to announce the launch of its Medical Radiography Technology (MRT) program aimed at addressing critical industry shortages, providing relief to the current workforce and extraordinary career opportunities for graduates.

Key Points: 
  • VANCOUVER, BC, Jan. 23, 2024 /CNW/ - Anderson College is proud to announce the launch of its Medical Radiography Technology (MRT) program aimed at addressing critical industry shortages, providing relief to the current workforce and extraordinary career opportunities for graduates.
  • "We welcome the opportunity to work with Anderson College to address the resource shortages we are experiencing in medical imaging," shared Kerri Smith, Manager, Clinical Education – Specialty Medical Imaging, FH, PHC, PHSA, VCH.
  • "Designed to tackle industry shortages head-on, our MRT program employs a revolutionary clinical immersion model that provides an unparalleled learning experience," said Cheryl Russell-Julien, Director of Academics, Anderson College.
  • Click for more information on the Medical Radiography Technology program or to learn about Anderson visit www.andersoncollege.com .

WELL Health Provides Business Update Demonstrating Focus on Profitable and Capital Efficient Growth

Retrieved on: 
Tuesday, January 16, 2024

OceanMD continues its successful growth journey and has started its work with the PHSA in British Columbia.

Key Points: 
  • OceanMD continues its successful growth journey and has started its work with the PHSA in British Columbia.
  • This has caused an unprecedented growth in the inbound interest in our owned and operated patient care business leading to an acceleration in our organic growth.
  • WELL's clinic recruitment and absorption program has demonstrated substantial growth and capital efficiency.
  • This is part of WELL's clinic recruitment and absorption program, which has made significant contributions to WELL's organic growth and reflects WELL's discipline regarding capital allocation.

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones

Retrieved on: 
Monday, August 14, 2023

By meeting strict FDA requirements for an ophthalmic approved formulation of bevacizumab, we believe we can enhance the standard of care.

Key Points: 
  • By meeting strict FDA requirements for an ophthalmic approved formulation of bevacizumab, we believe we can enhance the standard of care.
  • This represents approximately 3.5 million injections of off-label, repackaged bevacizumab each year in the United States alone.
  • Globally, the nine major markets account for an estimated $13.1 billion market for anti-VEGF drugs to treat retina diseases.
  • In August 2022, Outlook Therapeutics submitted a PHSA 351(a) BLA for ONS-5010 as an original biologic application.

WELL's OceanMD to Roll Out eReferral & eOrders Platform to Help Providers and Patients in British Columbia Digitize & Modernize Clinical Workflows

Retrieved on: 
Thursday, August 10, 2023

The Ocean Platform currently supports almost 1 million eReferrals and eConsults annually and is Canada's largest community of connected healthcare solutions.

Key Points: 
  • The Ocean Platform currently supports almost 1 million eReferrals and eConsults annually and is Canada's largest community of connected healthcare solutions.
  • OceanMD's ground-breaking platform is set to launch an array of digital services, such as eReferrals, eConsults, and eOrders, within British Columbia through a provincial platform.
  • The collaboration, cemented under a $38.5 million, sole source contract, promises to be a revolutionary tool for healthcare in British Columbia.
  • The platform streamlines clinical processes by digitizing traditional workflows and automatically updates both providers and patients on request statuses.

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023

These initiatives are focused on positioning Outlook Therapeutics as an upcoming leader in the anti-VEGF space by meeting FDA requirements for an ophthalmic approval.

Key Points: 
  • These initiatives are focused on positioning Outlook Therapeutics as an upcoming leader in the anti-VEGF space by meeting FDA requirements for an ophthalmic approval.
  • The ONS-5010 Biologics License Application (BLA) was submitted and accepted for filing by the FDA as a 351(a) stand-alone BLA.
  • As Outlook Therapeutics moves toward a potential launch in the United States, AmerisourceBergen’s commercialization support will expand to include additional services.
  • Outlook Therapeutics also submitted a Marketing Authorization Application (MAA) in Europe, which was validated for review in December 2022.

Emma Hider Joins Central 1 as Chief Financial Officer

Retrieved on: 
Thursday, February 2, 2023

VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- On Monday, February 6, Emma Hider will join Central 1 Credit Union as incoming Chief Financial Officer (CFO), and will transition into the full role as CFO on March 15, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- On Monday, February 6, Emma Hider will join Central 1 Credit Union as incoming Chief Financial Officer (CFO), and will transition into the full role as CFO on March 15, 2023.
  • Emma joins Central 1 from HSBC Hong Kong where as a managing director she had the responsibility for strategic planning and stress testing for the Asia Region.
  • Prior to working with HSBC, Emma also held senior manager roles with Raymond James Ltd., Provincial Health Services Authority (PHSA) and Citigroup.
  • Emma joins Central 1’s executive leadership team comprised of Sheila Vokey, President & CEO; Brent Clode, Chief Investment Officer; Erick Wong, Chief Product Officer; Dave Thomas, Chief Technology Officer; Julie Breuer, Interim Chief Client Experience Officer;  Kathy Parslow, Chief People & Corporate Services Officer; and Elaine Lajeunesse, Interim Chief Risk Officer.

Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Key Points: 
  • ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information, please visit the conference website .
  • The submission is supported by Outlook Therapeutics wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE.

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update

Retrieved on: 
Friday, May 13, 2022

This past quarter was marked by the achievement of the most important milestone to date for Outlook Therapeutics the submission of our BLA for ONS-5010.

Key Points: 
  • This past quarter was marked by the achievement of the most important milestone to date for Outlook Therapeutics the submission of our BLA for ONS-5010.
  • Outlook Therapeutics wet AMD clinical program for ONS-5010 consists of three completed clinical trials, NORSE ONE, NORSE TWO, and NORSE THREE.
  • With the successful completion of these clinical trials, Outlook Therapeutics submitted its BLA under the Public Health Service Act (PHSA) 351(a) regulatory pathway in March 2022.
  • We believe Outlook Therapeutics is in a strong financial position, stated Lawrence A. Kenyon, Chief Financial Officer of Outlook Therapeutics.

Outlook Therapeutics to Participate in Retina World Congress 2022

Retrieved on: 
Tuesday, May 10, 2022

ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Terry Dagnon, Chief Operations Officer of Outlook Therapeutics, will be a panelist at the Retina World Congress 2022 taking place May 12-15, 2022 in Fort Lauderdale, Florida.

Key Points: 
  • ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Terry Dagnon, Chief Operations Officer of Outlook Therapeutics, will be a panelist at the Retina World Congress 2022 taking place May 12-15, 2022 in Fort Lauderdale, Florida.
  • In March 2022, Outlook Therapeutics announced the submission to the U.S. Food and Drug Administration (FDA) of its new Biologics License Application (BLA) for ONS-5010 under the Public Health Service Act (PHSA) 351(a) regulatory pathway.
  • The ONS-5010 BLA was submitted on March 30, 2022 to FDA as a PHSA 351(a) new Biologics License Application (BLA).
  • For more information about the 2022 Retina World Congress, please visit the event website here .